Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGraphene Nanochem Regulatory News (GRPH)

  • There is currently no data for GRPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

26 Mar 2013 07:01

RNS Number : 8398A
Graphene NanoChem PLC
26 March 2013
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

This announcement is not an admission document. This announcement does not constitute or form part of, and should not be construed as, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company or securities in any other entity nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or investment decision in relation thereto. This announcement does not constitute a recommendation regarding any securities.

Any investment decision must be made exclusively on the basis of the final admission document dated 8 March 2013 and published by the Company (the "Admission Document"). A copy of the Admission Document is available on the Company's website, www.graphenenanochem.com.

 

Graphene NanoChem plc

("Graphene NanoChem" or the "Company")

Trading Update

 

26 March 2013

Graphene NanoChem, the nanotechnology and advanced materials company is pleased to announce a trading update ahead of its preliminary results for the financial year ended 31 December 2012 (the "Preliminary Results").

 

Highlights

 

·; Completion of placing raising £32.5 million before expenses

·; Completion of the reverse takeover of Platinum NanoChem Sdn. Bhd.

·; New contract with a tier-1 oil and gas major for supply of PlatClear into the EU for 2014

·; Expansion of speciality chemicals plant expected to commence in April 2013

·; Supply of graphene-enhanced PlatDrill to Scomi Group expected in July 2013

 

Current Trading and Outlook for the Enlarged Group

 

The Company announced today the successful completion of the placing raising £32.5 million before expenses (the "Placing"), the completion of the reverse takeover of Platinum NanoChem Sdn. Bhd. ("Platinum NanoChem") (the "Acquisition") and the change of name of the Company from Biofutures International plc ("Biofutures") to Graphene NanoChem. The Company and its subsidiaries following the Acquisition (the "Enlarged Group") intend to use the net proceeds of the Placing to:

·; Increase the capacity of the Enlarged Group's existing speciality chemicals plant;

·; Increase the capacity of the Enlarged Group's existing advanced nanomaterials plant to 250 tonnes per annum;

·; Fund technology commercialisation and graphene applications development efforts;

·; Increase the size and breadth of the Enlarged Group's intellectual property portfolio;

·; Support development of joint venture initiatives; and

·; Fund the Company's general working capital requirements.

 

Following today's completion, the Enlarged Group expects to draw down on its new £7.1 million revolving working capital facility from Malaysia Debt Ventures Berhad. Following the receipt of funds, the Enlarged Group will increase production at the Enlarged Group's speciality chemicals plant to full capacity, producing its PlatAmber and PlatClear second-generation biofuels from palm oil industry waste. These products are sold into the domestic and European markets through the Enlarged Group's existing customers, Chevron and Shell. Expanding on the existing sales of PlatClear into the EU, on 24 March 2013, the Enlarged Group shipped its first supply to a tier-1 oil and gas major in the EU under its 2013 contract. On 14 March 2013, the Enlarged Group also executed a new contract with the tier-1 oil and gas major for the supply of PlatClear into the EU for 2014.

 

Graphene NanoChem is finalising the award of various contracts for the graphene plant expansion and the planned capacity increase of the Enlarged Group's specialty chemicals plant and expects that work will begin in April 2013.

 

Following recent improvements in the taxation regime for the Malaysian palm oil refining industry, Graphene NanoChem intends to recommence refining operations at the crude palm oil refinery operated by its subsidiary, Zurex Corporation Sdn. Bhd. ("Zurex") in East Malaysia. Discussions have begun with both local feedstock suppliers and with Bank Rakyat, Zurex's existing bankers, with regard to obtaining a working capital facility appropriate to the refinery's capacity.

 

The Company looks forward to updating the market with further progress in the near term.

 

Year ended 31 December 2012

The Preliminary Results will relate to the business of Biofutures before the completion of the Acquisition, which comprises approximately 7.2 per cent. of the Enlarged Group's business. The Company expects to announce the Preliminary Results in early June 2013.

 

The Malaysian refining industry went through a pronounced slump in 2012, partly attributed to new government policies in Indonesia (since 1 October 2011), which provided Indonesian-based downstream players with relatively cheap crude palm oil at costs that rendered Malaysian-based independent refiners uncompetitive and operating on negative margins for each tonne of crude palm oil refined. This pressure, coupled with lower demand from Europe in 2012, led to reduced plant utilisation and negative refining margins for many Malaysian refiners, including Zurex.

 

In 2012, the utilisation of the Zurex refinery was limited to less than five per cent. Consequently Biofutures' revenues for the year were not significant and the loss from operations was substantially greater than management's expectations. This situation was one of the principal drivers for Biofutures' decision to seek alternative higher-margin business through the successful acquisition of Platinum NanoChem. The Acquisition valued Biofutures at £11.7 million and consequently the directors of Graphene NanoChem expect to write down the Biofutures intangible assets to a commensurate level in the Preliminary Results.

 

For further information:

Graphene NanoChem

Jespal Deol, Chief Executive Officer

 

Tel: +603 2282 3080

Panmure Gordon (NOMAD and Broker)

Callum Stewart

Tom Nicholson

 

 

Tel: +44(0) 20 7886 2500

Tel: +65 8614 7553

Citigate Dewe Rogerson

Ginny Pulbrook

 

Tel: +44(0) 20 7638 9571

Important notice

This announcement does not constitute an offer to sell or the solicitation of an offer to buy shares in the Company in any jurisdiction. Any such offer, if made, is being made pursuant to the Admission Document.

This announcement (or any part of it) is not to be distributed, reproduced, passed on, or the contents otherwise divulged, directly or indirectly, in or into the United States of America, Canada, Australia, the Republic of South Africa, Japan, or in any country, territory or possession where to do so may contravene local securities laws or regulations. Any failure to comply with the above restrictions may constitute a violation of the securities laws of any such jurisdiction.

The shares in the Company have not been nor will be registered under the United States Securities Act of 1933, as amended (the "US Securities Act"), or under the securities legislation of any state of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable state securities laws. The shares in the Company have not been nor will be registered under the relevant securities laws of Canada, Australia, the Republic of South Africa or Japan. There will be no offering of shares in the Company in or into the United States of America, Canada, Australia, the Republic of South Africa or Japan or in any country, territory or possession where to do so may contravene local securities laws or regulations.

Panmure Gordon, which is authorised and regulated in the United Kingdom in the conduct of investment business by the Financial Services Authority, is acting as nominated adviser to the Company with effect from the re-admission of the Company's share capital to trading on the AIM market operated by the London Stock Exchange plc, broker to the Company in connection with the Proposals and as sole bookrunner to the Company in connection with the Placing and will be acting for no one else in connection with the matters described herein. Panmure Gordon will not be responsible to anyone other than the Company for providing the protections afforded to clients of Panmure Gordon or for advising any other person on the contents of this announcement or the Proposals. No representation or warranty, express or implied, is made by Panmure Gordon as to the contents of this announcement (without limiting the statutory rights of any person to whom this announcement is issued). Apart from the responsibilities and liabilities, if any, which may be imposed on Panmure Gordon by the Financial Services and Markets Act 2000 (as amended), no liability whatsoever is accepted by Panmure Gordon for the accuracy of any information or opinions contained in this announcement or for the omission of any material information for which it is not responsible. Panmure Gordon's responsibilities as the nominated adviser under the AIM Rules are owed solely to the London Stock Exchange plc and are not owed to the Company or to any director of the Company or to any other person in respect of their decision to acquire shares in the Company in reliance on any part of this announcement. Panmure Gordon is not making any representation or warranty, express or implied, as to the contents of this announcement.

This announcement includes "forward-looking statements", which include all statements other than statements of historical facts including, without limitation, those regarding the Enlarged Group's financial position, business strategy, plans and objectives of management for future operations and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "plan", "project", "believes", "estimates", "aims", "intends", "can", "may", "expects", "forecasts", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Enlarged Group's control that could cause the actual results, performance or achievements of the Enlarged Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Enlarged Group's present and future business strategies and the environment in which the Enlarged Group will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Enlarged Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions in relation to any forward-looking statements contained herein to reflect any change in the Enlarged Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements in this announcement may not occur.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUVOAROAAOUUR
Date   Source Headline
7th Apr 20147:00 amRNSJoint Venture with Scomi
7th Apr 20147:00 amRNSHeads of Agreement with Emery Advanced Materials
6th Feb 20147:00 amRNSCommissioning Update
19th Dec 20137:00 amRNSProgress on Graphene Development
18th Dec 20137:00 amRNSUpdate on Senawang Facility
3rd Dec 20137:00 amRNSSenior Management Appointment
26th Nov 20137:00 amRNSTrading Update and Collaboration with Scomi
31st Oct 20139:21 amRNSTrading Update
21st Oct 20137:00 amRNSLahad Datu Refinery Resumes Operations
15th Oct 20137:00 amRNSUpgrade of Senawang Facility and Plant Shutdown
7th Oct 20138:23 amRNSContract renewal with Shell Malaysia
30th Sep 20137:00 amRNSInterim results
17th Sep 20137:00 amRNSPlatClear receives EPA Approval
5th Aug 20137:00 amRNSContract win
1st Aug 20137:00 amRNSContract win
28th Jun 20132:00 pmRNSResult of AGM
3rd Jun 20139:45 amRNSFinal Results
3rd Jun 20137:15 amRNSFinal Results
30th May 201312:29 pmRNSNotice of Results
29th May 20137:00 amRNSNew customer
22nd Apr 20137:00 amRNSContract Volume Doubled
3rd Apr 20137:00 amRNSDirector/PDMR Shareholding
26th Mar 20137:01 amRNSTrading Update
26th Mar 20137:00 amRNSFirst Day of Dealings
25th Mar 201310:44 amRNSResult of General Meeting
15th Mar 201312:59 pmRNSHolding(s) in Company
11th Mar 20139:55 amRNSSchedule 1 - Biofutures International Plc
11th Mar 20137:30 amRNSRestoration - Biofutures International Plc
8th Mar 20136:04 pmRNSAcquisition and Placing
4th Feb 201310:52 amRNSChange of Company Secretary & Registered Office
10th Dec 20121:00 pmRNSSuspension - Biofutures International Plc
10th Dec 20121:00 pmRNSTemporary Suspension
27th Sep 20127:00 amRNSHalf Yearly Report
30th Aug 20124:40 pmRNSSecond Price Monitoring Extn
30th Aug 20124:35 pmRNSPrice Monitoring Extension
26th Jul 20127:00 amRNSResolution of Dispute
15th Jun 201210:23 amRNSReplacement Result of AGM
15th Jun 201210:12 amRNSResult of AGM
28th May 20127:00 amRNSNotice of AGM
23rd Mar 20129:00 amRNSBoard Changes
13th Feb 20129:00 amRNSResult of Arbitration
11th Jan 20128:58 amRNSHolding(s) in Company
27th Oct 20118:33 amRNSPipeline Installation & Connection Contract Update
29th Sep 201111:15 amRNSHalf Yearly Report for 6 months ended 30 June 2011
29th Jun 201111:57 amRNSResult of AGM & Board Changes
25th May 20117:00 amRNSFinal Results
29th Mar 20111:58 pmRNSOperations and Strategy Update
31st Jan 20112:20 pmRNSTR-1 Notification of Major Interest in Shares
10th Jan 20118:51 amRNSBoard Appointment
6th Jan 20117:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.